Hyponatremia following Losartan therapy in a patient of Cerebro Vascular Attack- A Case report.
Hyponatremia following Losartan therapy in a patient of Cerebro Vascular Attack
Keywords:
Hyponatremia, Losartan, Hypertension, Cerebro Vascular AttackAbstract
Abstract: Electrolyte imbalances are frequently encountered with the use of Losartan. Losartan is a first line
drug used for hypertension with less side effects. Herein we report a case of a 60year old male patient
presenting to EMD(Emergency medicine Department) with slurred speech & vomiting 3-4 times for past
1week who developed hyponatremia secondary to losartan. Patient is a known case of cerebro vascular
attack since 3years, had associated hypertension and diabetes for last 10years. On admission patient’s
serum sodium level was 119meq/l which improved by daily sodium infusion. Hyponatremia can emerge as
a serious adverse effect of losartan therapy, although not much documented in scientific literature. [Shah V
Natl J Integr Res Med, 2019; 10(4):83-85]
References
2) Desai A (2008) Hyperkalemia associated with inhibitors of the renin–angiotensin–aldosterone system: balancing risk and benefit. Circulation 118:1609–1611
3) Lath R. Hyponatremia in neurological disease in ICU. Indian J Crit Care Med. 2005;9:47–51.
4) Bussmann C, Bast T, Rating D. Hyponatraemia in children with acute CNS disease: SIADH or cerebral salt wasting? Childs Nerv Syst. 2001;17:58–62.
5) Nigro N, Winzeler B, Suter-Widmer I, Schuetz P, Arici B, Bally M, Blum C, Bingisser R, Bock A, Huber A, Müller B, Nickel CH, Christ-Crain M
J Am Geriatr Soc. 2015 Mar; 63(3):470-5.
6) Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904–912.
7) Das S, Bandyopadhyay S, Ramasamy A Prabhu VV, Pachiappan S. A case of losartan-induced severe Hyponatremia J Pharmacol Pharmacother 2015;6:219-21.
8)Sai-Zhen Chen, Pei-Pei Pan, Lei-Bin Shen, Shan-Shan Xu, Da-Peng Dai, Pei-Wu Geng, Jie Cai, Jian-Ping Cai, and Guo-Xin Hu.Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro. 2014; 52: 732-738. doi: 10.5414/CP202071.
9) Francesco P. Cappuccio, M.D.,Nirmala D. Markandu, R.S.N.,Giuseppe A. Sagnella, Ph.D.,Donald R.J. Singer, M.R.C.P.,Michelle A. Miller, B.Sc.,Martin G. Buckley, B.Sc.,Graham A. MacGregor, F.R.C.P.∗ Correspondence information about the author F.R.C.P. Graham A. MacGregor
Blood Pressure Unit, Department of Medicine, St. George's Hospital Medical School, London, United Kingdom
